Efficacy of 4 mg Zoledronic Acid Plus Colaren vs 4mg Zoledronic Acid + Conventional Treatment for Secondary Osteoporosis in HIV Positive and Negative Men
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Change from baseline of Bone mineral density at 12 months
研究概览
简要总结
Clinical trial to assess the effectiveness of the supplement Colaren® associated with zoledronic acid 4mg/annually in the treatment of osteoporosis secondary, compared to standard treatment plus zoledronic acid 4mg/annually. The standard treatment will include 1gr of calcium/day and vitamin D supplement. In both cases, vitamin D levels will be determinated, which should remain at more than 30 ng/mL.
Including men with osteoporosis secondary to HIV and men with osteoporosis secondary to any other cause (HIV negative). Vitamin D levels, bone densitometry and markers of metabolism, bone formation and bone resorption will be assessment. The all parameters above will be assessed basally (before the start of treatment), after starting the treatment, an assessment will be made at 12 weeks where vitamin D levels and bone markers will be measured. Meanwhile, at week 24 assess only vitamin D levels; and finally, at week 52 all parameters mentioned above will be measured.
详细描述
This study is a clinical trial to assess the effectiveness of the supplement Colaren® associated with annually zoledronic acid 4mg, in the treatment of osteoporosis secondary or not to HIV infection, compared to standard treatment plus zoledronic acid 4mg/annually. The standard treatment will include 1gr of calcium/day and vitamin D supplement. In both cases, vitamin D levels will be evaluated, which should remain at more than 30 ng/mL.
Including men with osteoporosis secondary to HIV and men with osteoporosis secondary to any other cause (HIV negative). Vitamin D levels, bone densitometry and markers of metabolism, bone formation and bone resorption will be assessment. The all parameters above will be assessed basally (before the start of treatment), after starting the treatment, an assessment will be made at 12 weeks where vitamin D levels and bone markers will be measured. Meanwhile, at week 24 assess only vitamin D levels; and finally, at week 52 all parameters mentioned above will be measured.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Adult males 18 to 65 years old.
- •HIV diagnosis (HIV positive group) or negative HIV serology (HIV negative group).
- •Patients receiving HAART and sustained virologic control for at least two years.
- •Patients meeting diagnostic criteria for osteoporosis.
- •Subjects willing to participate voluntarily in this study and give a written consent.
- •Estimated glomerular filtration rate >60 mL/min (Using CKD-EPI formula).
排除标准
- •Use of calcium, vitamin D or any other drug with bone activity during the last 90 days previous to the study.
- •Use of herbs or herb products during the last 90 days previous to the study.
- •Positive test for HCV or HBV.
- •Patients who cannot be submitted to complete examination for variable analysis.
- •Glomerular filtration rate <60 mL/minute.
- •Active liver disease.
- •Non-compliance to treatment (less than 90%).
- •Patients who are not willing to continue participating.
- •Non-inclusion criteria:
- •Female patients.
- •Use of immunosuppressive o immunomodulatory treatment 90 days previous to selection.
- •Use of prohibited drugs for the study like: antiestrogens, corticosteroids (doses greater than 7.5mg of prednisone/day) 90 days previous to selection.
- •Use of hormone therapy.
- •Patients with history or actual use of chemotherapy.
- •Patients deprived of freedom or imprisoned patients with mental illnesses.
- •Participant is part of another clinical trial or nutritional program.
- •Hypogonadism diagnosis with not having received hormonal replacement previous to the study.
- •Primary osteoporosis diagnosis.
研究组 & 干预措施
1 Arm: Experimental
Experimental: 4 mg zoledronic acid plus colaren ® This arm include: 20 man with HIV infection plus osteoporosis
干预措施: Colaren in HIV positive (Drug)
2 Arm: Active comparator
Active comparator: 4mg zoledronic acid + standard treatment (or conventional treatment) This arm include: 20 man with HIV infection plus osteoporosis
干预措施: standard treatment in HIV positive (Drug)
3 Arm: Experimental
Experimental: 4 mg zoledronic acid plus colaren ® This arm include: 20 man without HIV infection plus osteoporosis
干预措施: Colaren in HIV negative (Drug)
4 Arm: Active comparator
Active comparator: 4mg zoledronic acid + standard treatment (or conventional treatment) This arm include: 20 man without HIV infection plus osteoporosis
干预措施: standard treatment in HIV negative (Drug)
结局指标
主要结局
Change from baseline of Bone mineral density at 12 months
时间窗: Time frame: from baseline and 12 months under treatment.
Bone mineral density through Dual-energy X-ray absorptiometry (DXA scan) measure. Classification: Normal: T-score ≥ -1.0 Osteopenia: -2.5 \< T-score \< -1.0 Osteoporosis: T-score ≤ -2.5 Severe osteoporosis: T-score ≤ -2.5 with fragility fracture
Change in Bone turnover markers (from baseline to 12 months under treatment)
时间窗: Time frame: from baseline, 3 and 12 months under treatment.
Plasma measure of (through LEGENDplex (Multiplex)): Bone formation panel that include: Osteoprotegerin (OPG) measure in pg/mL, Alkaline Phosphatase Liver/Bone/Kidney (ALPL) measure in pg/mL, LEPTINA measure in pg/mL and Bone Morphogenetic Protein 2 (BMP-2) measure in pg/mL. Bone resorption panel that include: Osteopontin (OPN) measure in pg/mL, Acid Phosphatase 5 Tartrate Resistant (ACP5) measure in pg/mL, RANKL measure in pg/mL, Tumor Necrosis Factor Alpha (TNF-α) measure in pg/mL, Interleukin 6 (IL-6) measure in pg/mL, Parathyroid Hormone (PTH) measure in pg/mL, Interleukin 1 beta (IL-1β) measure in pg/mL, Dickkopf WNT Signaling Pathway Inhibitor 1 (DKK-1) measure in pg/mL.
次要结局
- Tolerability of colaren vs standard treatment (conventional treatment): grading the severity of Adult and Pediatric Adverse Events Version 2.0(Time frame: evaluate the tolerability from month 1, 3, 6, 9 and 12, under supplementation)
研究者
Luz Alicia González Hernández
Head of HIV Unit in Hospital Civil de Guadalajara
University of Guadalajara